Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011; 29: 4387–4393.

Published: 4th April 2012

Authors: Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T et al. et al.


The addition of a year of chemotherapy (oral fluoropyrimidine derivative S-1) improved both 5-year relapse-free survival (65 versus 53 per cent) and overall survival 72 versus 61 per cent: hazard ratio 0.67, 95 per cent confidence interval 0.54 to 0.83.

Pubmed Link

Your comments